Instituto RosenbuschBUE:ROSE -0.61%39 FCF Yield % is 5.72 as of Jul. 01, 2026, which is 24% above its 10-year median of 4.63. GuruFocus rates BUE:ROSE with a GF Score™ of 39/100 and a GF Value™ of ARS61.82 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Instituto Rosenbusch ranks better than 76.27% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Instituto Rosenbusch FCF Yield % Related Terms
Instituto Rosenbusch FCF Yield % Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:ROSE vs ZTS, UTHR, VTRS: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch (BUE:ROSE) has a FCF Yield % of 5.72 as of Jul. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Instituto Rosenbusch and its competitors. This is 24% above median its historical median of 4.63. According to the industry distribution chart, Instituto Rosenbusch ranks #238 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 23.7%.
Is Instituto Rosenbusch's FCF Yield % too high?
Instituto Rosenbusch's current FCF Yield % of 5.72 is 24% above median its 10-year median of 4.63. The Drug Manufacturers industry median FCF Yield % is 0.67. Instituto Rosenbusch's value of 5.72 is 753.7% above this industry median. Based on the distribution chart, Instituto Rosenbusch ranks #238 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #238 out of 1003 companies for FCF Yield %. This places Instituto Rosenbusch in the top 24% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Instituto Rosenbusch's value of 5.72 is 753.7% above this benchmark. While the company's 10-year median is 4.63 vs. the industry median of 0.67, Instituto Rosenbusch has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instituto Rosenbusch's current FCF Yield % of 5.72 is 753.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current FCF Yield % is 5.72, which is 24% above median its own 10-year median of 4.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.82, compared to a current price of ARS163.00 — trading 163.7% above its estimated fair value. The current FCF Yield % is 5.72, which is 24% above median its 10-year median of 4.63 and 753.7% above the Drug Manufacturers industry median of 0.67. Instituto Rosenbusch's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current FCF Yield % is 5.72 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS163.00 is trading 163.7% above its estimated GF Value™ of ARS61.82.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
FCF Yield %: 5.72 (24% above median its 10-year median of 4.63)
GF Value™: ARS61.82 vs. price of ARS163.00 (163.7% above fair value)
Industry Position: 753.7% above the Drug Manufacturers median (#238 of 1003)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
39GF Score
Get the complete analysis for BUE:ROSE
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
